Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viracta Therapeutics (VIRXResearch Report), Altimmune (ALTResearch Report) and Icon (ICLRResearch Report) with bullish sentiments.

Viracta Therapeutics (VIRX)

Evercore ISI analyst Joshua Schimmer maintained a Buy rating on Viracta Therapeutics today and set a price target of $15.00. The company’s shares closed last Thursday at $3.04, close to its 52-week low of $2.18.

According to TipRanks.com, Schimmer is a 4-star analyst with an average return of 8.0% and a 49.6% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Rocket Pharmaceuticals, and Aeglea Biotherapeutics.

Currently, the analyst consensus on Viracta Therapeutics is a Strong Buy with an average price target of $20.33, representing a 706.7% upside. In a report issued on March 16, Leerink Partners also maintained a Buy rating on the stock with a $11.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Altimmune (ALT)

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Altimmune today and set a price target of $25.00. The company’s shares closed last Thursday at $7.05, close to its 52-week low of $5.78.

According to TipRanks.com, Bayko is a 4-star analyst with an average return of 8.5% and a 44.1% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Kiniksa Pharmaceuticals.

Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $25.00, a 281.7% upside from current levels. In a report issued on March 15, Jefferies also maintained a Buy rating on the stock with a $30.00 price target.

Icon (ICLR)

In a report released today, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on Icon, with a price target of $280.00. The company’s shares closed last Thursday at $235.97.

According to TipRanks.com, CFA ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -16.1% and a 37.8% success rate. CFA covers the Healthcare sector, focusing on stocks such as Patterson Companies, AmerisourceBergen, and Oak Street Health.

Currently, the analyst consensus on Icon is a Moderate Buy with an average price target of $288.00, which is a 24.9% upside from current levels. In a report issued on March 7, Mizuho Securities also maintained a Buy rating on the stock with a $272.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VIRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos